Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial

被引:48
|
作者
Gault, Emma Jane [1 ]
Perry, Rebecca J. [1 ]
Cole, Tim J. [2 ]
Casey, Sarah [3 ]
Paterson, Wendy F. [1 ]
Hindmarsh, Peter C. [4 ]
Betts, Peter [5 ]
Dunger, David B. [6 ]
Donaldson, Malcolm D. C. [1 ]
机构
[1] Univ Glasgow, Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland
[2] UCL Inst Child Hlth, MRC Ctr Epidemiol Child Hlth, London, England
[3] Royal Hosp Sick Children, Dept Clin Trials, Dept Pharm, Glasgow G3 8SJ, Lanark, Scotland
[4] UCL Inst Child Hlth, Clin & Mol Genet Unit, London, England
[5] Southampton Univ Hosp NHS Trust, Dept Paediat, Southampton, Hants, England
[6] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England
来源
BMJ-BRITISH MEDICAL JOURNAL | 2011年 / 342卷
关键词
GROWTH-HORMONE TREATMENT; ESTROGEN REPLACEMENT; GIRLS; THERAPY; MULTICENTER; NORMALIZATION; MANAGEMENT; STATURE; AGE;
D O I
10.1136/bmj.d1980
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine the effect of oxandrolone and the timing of pubertal induction on final height in girls with Turner's syndrome receiving a standard dose of growth hormone. Design Randomised, double blind, placebo controlled trial. Setting 36 paediatric endocrinology departments in UK hospitals. Participants Girls with Turner's syndrome aged 7-13 years at recruitment, receiving recombinant growth hormone therapy (10 mg/m(2)/week). Interventions Participants were randomised to oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day) or placebo from 9 years of age. Those with evidence of ovarian failure at 12 years were further randomised to oral ethinylestradiol (year 1, 2 mu g daily; year 2, 4 mu g daily; year 3, 4 months each of 6, 8, and 10 mu g daily) or placebo; participants who received placebo and those recruited after the age of 12.25 years started ethinylestradiol at age 14. Main outcome measure Final height. Results 106 participants were recruited, of whom 14 withdrew and 82/92 reached final height. Both oxandrolone and late pubertal induction increased final height: by 4.6 (95% confidence interval 1.9 to 7.2) cm (P=0.001, n=82) for oxandrolone and 3.8 (0.0 to 7.5) cm (P=0.05, n=48) for late pubertal induction with ethinylestradiol. In the 48 children who were randomised twice, the effects on final height (compared with placebo and early induction of puberty) of oxandrolone alone, late induction alone, and oxandrolone plus late induction were similar, averaging 7.1 (3.4 to 10.8) cm (P<0.001). No cases of virilisation were reported. Conclusion Oxandrolone had a positive effect on final height in girls with Turner's syndrome treated with growth hormone, as did late pubertal induction with ethinylestradiol at age 14 years. However, these effects were not additive, so using both had no advantage. Oxandrolone could, therefore, be offered as an alternative to late pubertal induction for increasing final height in Turner's syndrome.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
    Brooklyn, TN
    Dunnill, MGS
    Shetty, A
    Bowden, JJ
    Williams, JDL
    Griffiths, CEM
    Forbes, A
    Greenwood, R
    Probert, CS
    GUT, 2006, 55 (04) : 505 - 509
  • [22] Ornidazol for prophylaxis of postoperative Crohn's disease: Final results of a double blind placebo controlled trial
    Rutgeerts, P
    Van Assche, G
    D'Haens, G
    Baert, F
    Noman, M
    Aerden, I
    Geboes, K
    D'Hoore, A
    Penninckx, F
    GASTROENTEROLOGY, 2002, 122 (04) : A80 - A80
  • [23] The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial
    Lord, J.
    Thomas, R.
    Fox, B.
    Acharya, U.
    Wilkin, T.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2006, 113 (07) : 817 - 824
  • [24] Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial
    Egsmose, C
    Hansen, TM
    Andersen, LS
    Beier, JM
    Christensen, L
    Ejstrup, L
    Peters, ND
    vanderHeijde, DMFM
    ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (01) : 32 - 36
  • [25] The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
    Attia, John R.
    Holliday, Elizabeth
    Weaver, Natasha
    Peel, Roseanne
    Fleming, Kerry C.
    Hure, Alexis
    Wiggers, John
    McEvoy, Mark
    Searles, Andrew
    Reeves, Penny
    Ranasinghe, Priyanga
    Jayawardena, Ranil
    Samman, Samir
    Luu, Judy
    Rissel, Chris
    Acharya, Shamasunder
    ACTA DIABETOLOGICA, 2022, 59 (07) : 965 - 975
  • [26] The effect of zinc supplementation on glucose homeostasis: a randomised double-blind placebo-controlled trial
    John R. Attia
    Elizabeth Holliday
    Natasha Weaver
    Roseanne Peel
    Kerry C. Fleming
    Alexis Hure
    John Wiggers
    Mark McEvoy
    Andrew Searles
    Penny Reeves
    Priyanga Ranasinghe
    Ranil Jayawardena
    Samir Samman
    Judy Luu
    Chris Rissel
    Shamasunder Acharya
    Acta Diabetologica, 2022, 59 : 965 - 975
  • [27] Effect of timing of intraoperative administration of paracetamol on postoperative shivering: A randomised double-blind controlled trial
    Mohta, Medha
    Mounika, T. Bindu
    Tyagi, Asha
    INDIAN JOURNAL OF ANAESTHESIA, 2023, 67 (12) : 1071 - 1076
  • [28] Efficacy of Memantine for Agitation in Alzheimer's Dementia: A Randomised Double-Blind Placebo Controlled Trial
    Fox, Chris
    Crugel, Monica
    Maidment, Ian
    Auestad, Bjorn Henrik
    Coulton, Simon
    Treloar, Adrian
    Ballard, Clive
    Boustani, Malaz
    Katona, Cornelius
    Livingston, Gill
    PLOS ONE, 2012, 7 (05):
  • [29] A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING CYSTEAMINE IN HUNTINGTON'S DISEASE
    Bonneau, Dominique
    Bachoud-Levi, Anne-Catherine
    Durr, Alexandra
    Goizet, Cyril
    Azulay, Jean-Philippe
    Simonin, Clemence
    Tranchant, Christine
    Calvas, Fabienne
    Krystkowiak, Pierre
    Olivier, Audrey
    Saudou, Frederic
    Maison, Patrick
    Allain, Philippe
    Verny, Christophe
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A101 - A102
  • [30] Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
    van Rhee, Frits
    Wong, Raymond S.
    Munshi, Nikhil
    Rossi, Jean-Francois
    Ke, Xiao-Yan
    Fossa, Alexander
    Simpson, David
    Capra, Marcelo
    Liu, Ting
    Hsieh, Ruey Kuen
    Goh, Yeow Tee
    Zhu, Jun
    Cho, Seok-Goo
    Ren, Hanyun
    Cavet, James
    Bandekar, Rajesh
    Rothman, Margaret
    Puchalski, Thomas A.
    Reddy, Manjula
    van de Velde, Helgi
    Vermeulen, Jessica
    Casper, Corey
    LANCET ONCOLOGY, 2014, 15 (09): : 966 - 974